TPP Global Development (United Kingdom) a preclinical-stage drug development company focused on acquiring and developing early-stage intellectual property in the CNS, inflammation and oncology sectors, closed a $12.2M Series A financing. Participants include Scottish Venture Fund.

Action Pharma (Denmark) a clinical-stage biopharmaceutical company focused on acute kidney injury in patients undergoing cardiac surgery and inflammation, closed a $6.3M Series C financing. Participants include Sunstone Capital, Global Life Science Ventures, SLS Invest and InnovationsKapital.

Avraham Pharmaceuticals (Israel) a clinical-stage small molecule company focused on the treatment of Alzheimer’s, closed a $9M Series A financing. Participants include Yissum Research Development Company, Pontifax and Clal Biotechnology Industries.

Implanet (France) a commercial-stage developer of surgical implants for orthopedic and spine surgery, closed a $10.1M Series D financing. Participants include CM-CIC Private Equity, Edmond de Rothschild Investment Partners, Wellington Partners Venture Capital and Seventures Partners.

Aquinox Pharmaceuticals (Canada) a preclinical-stage small-molecule drug company focused on cancer, immune disorders and metabolic disease, closed a $25M Series B financing. Participants include Ventures West Capital, Johnson & Johnson Development Corp., Baker Brothers Investments, BC Advantage Funds and Pfizer Venture Investments.

Pharnext (France) a preclinical-stage biopharmaceutical company focused on treatment for Charcot-Marie-Tooth and other neuromuscular diseases, closed a $5.8M Series A financing. Participants include Truffle Capital, Aurinvest Capital and Financière Boscary.

• View 1 Comment...

Complix (Belgium) a preclinical-stage biopharmaceutical focused on alphabody therapeutics for autoimmune and infectious diseases, closed a $6.2M Series A financing. Participants include Vesalius Biocapital, LRM and CRP Santé.

Cytheris (France) a clinical-stage biopharmaceutical immune modulation company focused on HIV, HCV and oncology, closed a $14.3M Series D financing. Participants include CDC Entreprises, Gestion, Caisse de dépôt et Placement du Québec, CDC Innovation, Crédit Agricole Private Equity and Forbion Capital Partners.

Funxional Therapeutics (United Kingdom) a clinical-stage small molecule company focused on asthma, COPD and other respiratory disorders, closed a $12.2M Series B financing. Participants include Ventech, Index Ventures and Novo Ventures.

Caprotec Bioanalytics (Germany) a commercial-stage company focused on a mass spec technology of multifunctional small molecules used to target, capture and isolate proteins based on their functionality, closed a $4.9M Series B financing. Participants include Creathor Venture, IBB Beteiligungsgesellschaft and ERP Startfonds.